Overview

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Status:
RECRUITING
Trial end date:
2035-12-01
Target enrollment:
Participant gender:
Summary
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
Phase:
PHASE1
Details
Lead Sponsor:
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators:
C17 Council
Children's Cancer Institute Australia (CCIA)
Kazia Therapeutics Limited
Medical Research Future Fund
The Hospital for Sick Children
Treatments:
Irinotecan
Temozolomide